Nanobiotix is a clinical-stage biotechnology company developing nanotechnology-based cancer therapies. Its lead product candidate, NBTXR3 (hafnium oxide nanoparticles), is designed to be injected into tumors to amplify the effect of radiotherapy. The company focuses on solid tumors and partners with oncology clinicians and industry for late-stage development and commercialization pathways.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 0 | — | -57 | — |
| 2023 | 30.1 | — | -39.7 | — |
| 2024 | -11.6 | -138.6% | -68.1 | — |
| 2025 | 29.6 | — | -24 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Omada Health, Inc. (OMDA), Northeast Bank (NBN), Mission Produce, Inc. (AVO), STAAR Surgical Company (STAA), Power Solutions International, Inc. (PSIX), Karat Packaging Inc. (KRT)